Increasing Trauma/LOQTEQ® sales in Q3/2013, empiric observations show favorable behavior of LOQTEQ®
(Thomson Reuters ONE) -
aap Implantate AG /
Increasing Trauma/LOQTEQ® sales in Q3/2013, empiric observations show favorable
behavior of LOQTEQ®
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE) achieved
sales in the third quarter of 2013 of EUR 8.8 million (+2%; previous year: EUR
8.6 million). These figures are in line with the given forecast from august.
Therefore, total sales in the first nine months increase by 3% to EUR 28.4
million (previous year: EUR 27.5 million).
It must be emphasized that sales in the Trauma segment increased by 53%
(compared to the third quarter of 2012) and by 63% compared to last years first
nine months. Trauma sales increased from EUR 1.5 million (Q3/2012) to EUR 2.3
million and from EUR 4.0 million (9m/2012) to EUR 6.5 million in the first nine
months of 2013 respectively. The strong sales growth was driven mainly by sales
in SMIT and BRICS countries. The first explantations of our LOQTEQ® plates show
certain advantages compared to established competitive products, especially
relating to the so called cold welding issue (a joining of the plate and the
screw which complicate the proper removal of the implant). So far, no such
complaints have been filed to aap for any LOQTEQ® product. In an ongoing in-
vitro study, this empirical and highly relevant feature is to be explored
further to be able to make a statistical proven and evidence-based statement.
Sales for bone cements and cementing techniques in the Biomaterials segment
begin to speed up after the temporary reduction in the first half of 2013.
During the fourth quarter, a full recovery is expected.
The evaluation process of the strategic options for EMCM is ongoing.
aap plans to publish the full Q3 2013 report on November 11, 2013.
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de, or download the Company's investor relations app from the
Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich(at)aap.de
Â
Press Release aap 10-08-2013:
http://hugin.info/130121/R/1734251/580828.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1734251]
Unternehmensinformation / Kurzprofil:
Datum: 08.10.2013 - 12:10 Uhr
Sprache: Deutsch
News-ID 303863
Anzahl Zeichen: 5150
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Increasing Trauma/LOQTEQ® sales in Q3/2013, empiric observations show favorable behavior of LOQTEQ®"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
